News

Kurin, Inc. Reports Record Third Quarter Revenues

Kurin, Inc. receives CE Mark for its novel Kurin Lock®

Kurin Inc. Responds to Allegations Published by Magnolia Medical Regarding Patent Infringement

Kurin, Inc. CEO Addresses Patent Infringement Lawsuit Brought by Magnolia Medical

Kurin, Inc. receives FDA 510k clearance for its novel Kurin Lock with peripheral IV infusion set.

Kurin, Inc. announces clinical results on Kurin® efficacy from Central Texas Veterans Health Care System

Kurin, Inc. Announces Agreement with Premier for Kurin Lock® to help impact contaminated blood cultures

Kurin, Inc. Announces Educational Website on the Importance of Improving Value of the Blood Culture Test

Clinical results of Kurin specimen diversion technology signal a shift in the blood culture collection standard of care.

Kurin CEO responds to Magnolia Medical Countersuit Press Release

Kurin, Inc. Receives Allowance from United States Patent and Trademark Office for Patent on Innovative Blood Culture Collection Device

Kurin, Inc. announces clinical study results of the Kurin Lock™ blood culture initial specimen diversion device at the APIC Annual Conference.

Kurin, Inc. sues Magnolia Medical for misleading consumers about FDA clearance and efficacy

Kurin, Inc. Receives Allowance from United States Patent and Trademark Office for Patent on Innovative Blood Culture Collection Device

ML-021 Rev A